Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Short-term Investments (2016 - 2025)

Assembly Biosciences has reported Short-term Investments over the past 11 years, most recently at $189.7 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 157.21% year-over-year to $189.7 million; the TTM value through Dec 2025 reached $189.7 million, up 157.21%, while the annual FY2025 figure was $189.7 million, 157.21% up from the prior year.
  • Short-term Investments for Q4 2025 was $189.7 million at Assembly Biosciences, down from $210.0 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $210.0 million in Q3 2025 and troughed at $19.6 million in Q3 2023.
  • A 5-year average of $88.3 million and a median of $73.7 million in 2022 define the central range for Short-term Investments.
  • Biggest five-year swings in Short-term Investments: crashed 63.77% in 2023 and later surged 240.09% in 2024.
  • Year by year, Short-term Investments stood at $101.0 million in 2021, then plummeted by 61.2% to $39.2 million in 2022, then soared by 181.71% to $110.4 million in 2023, then crashed by 33.21% to $73.7 million in 2024, then soared by 157.21% to $189.7 million in 2025.
  • Business Quant data shows Short-term Investments for ASMB at $189.7 million in Q4 2025, $210.0 million in Q3 2025, and $51.0 million in Q2 2025.